Ignite Creation Date:
2025-12-24 @ 5:43 PM
Ignite Modification Date:
2026-01-05 @ 1:13 AM
Study NCT ID:
NCT03410368
Status:
UNKNOWN
Last Update Posted:
2018-07-17
First Post:
2017-12-28
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
NK Cell-based Immunotherapy as Maintenance Therapy for Small-Cell Lung Cancer.
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D055752', 'term': 'Small Cell Lung Carcinoma'}], 'ancestors': [{'id': 'D002283', 'term': 'Carcinoma, Bronchogenic'}, {'id': 'D001984', 'term': 'Bronchial Neoplasms'}, {'id': 'D008175', 'term': 'Lung Neoplasms'}, {'id': 'D012142', 'term': 'Respiratory Tract Neoplasms'}, {'id': 'D013899', 'term': 'Thoracic Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'Patients with small-cell lung cancer receive autologous NK cells adoptive cancer immunotherapy as a maintenance therapy in the presence of stable disease (SD), partial remission (PR) or complete remission (CR) after the first-line chemotherapy.'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 120}}, 'statusModule': {'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'RECRUITING', 'startDateStruct': {'date': '2018-04-01', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2018-07', 'completionDateStruct': {'date': '2020-07-01', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2018-07-15', 'studyFirstSubmitDate': '2017-12-28', 'studyFirstSubmitQcDate': '2018-01-18', 'lastUpdatePostDateStruct': {'date': '2018-07-17', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2018-01-25', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2019-06-01', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Progression-free survival(PFS)', 'timeFrame': '20 months', 'description': 'Progression-free survival is defined as the time from randomization to first observation of progression or date of death (from any cause). Progression will be evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1. Patients who do not progress or not die will be censored on the date of their last tumor assessment, i.e. on the last date that we really know that the patient is considered as "progression-free".'}], 'secondaryOutcomes': [{'measure': 'Overall survival(OS)', 'timeFrame': '20 months', 'description': 'Overall survival, defined as the time from randomization until death due to any cause. For patients who do not die, time to death will be censored at the time of the last contact.'}, {'measure': 'Evaluate the change of the quality of life for all patients', 'timeFrame': '20 months', 'description': "Patients' quality-of-life will be assessed by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire LC-13 at baseline and after every two courses of adoptive cellular transfer in study group or every visit in control group."}]}, 'oversightModule': {'isUsExport': False, 'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['maintenance therapy', 'immunotherapy', 'adoptive cell transfer', 'natural killer cell'], 'conditions': ['Small Cell Lung Cancer']}, 'descriptionModule': {'briefSummary': 'Natural killer (NK) cells can kill a broad array of tumor cells in a non-major histocompatibility complex(MHC)-restricted manner. Adoptive transfer of NK may prolong the survival of patients with cancer. This study evaluates the efficacy and safety of NK cell-based immunotherapy for small-cell lung cancer (SCLC) after first-line chemotherapy. Half of the participants will receive autologous adoptive transfer of NK cells after the response from first-line chemotherapy, while the other half will be followed up in routine clinal practice.', 'detailedDescription': 'The small-cell lung cancer (SCLC) is very sensitive to the standard-of-care first-line chemotherapy and/or radiotherapy, but it will ultimately progress or relapse and develop early resistance to conventional treatments. No effective maintenance therapy except for wath and wait after first-line therapy at present.\n\nNK cells constitute the major component of the innate immune system and kill tumor cells in a non-MHC-restricted manner. In our previous pilot study and other reports, adoptive transfer of autologous NK cells expanded ex vivo was very well tolerant and effective.\n\nThere is no prospective trial on the maintenance therapy of SCLC after first-line chemotherapy based on autologous NK cells. The purpose of this phase II clinical research is to evaluate the efficacy and safety of autologous NK cells as the maintenance therapy after the first-line treatment, comparing with conventional observation group.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Histologically or cytologically confirmed small cell lung cancer.\n* Having completed first-line therapy in the presence of stable disease (SD), partial remission (PR) or complete remission (CR) status.\n* Age ≥18 years.\n* Karnofsky Performance Status (KPS) ≥80.\n* Important organs:cardiac ejection fraction \\>50%; Pulse Oxygen Saturation(SpO2) \\>90%; creatinine (Cr) ≤ 2.5 times the normal range; alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3 times the normal range, total bilirubin (TBIL)≤2.0mg/dl (34.2umol/L);Hgb≥60g/L.\n* Without contraindication of apheresis and cell isolation.\n* Patients and their families having the willingness to participate in clinical trial with signed written informed consent.\n\nExclusion Criteria:\n\n* Patient having an active rheumatic immunologic disease.\n* Uncontrolled bacterial, fungal or viral infection.\n* human immunodeficiency virus(HIV), hepatitis B virus infection(HBV), hepatitis C virus(HCV) infection.\n* History of organ transplantation and hemopoietic stem cell transplantation.\n* Pregnant or lactating women.\n* Patients using immunosuppressive agents within the first 3 months of the study or received glucocorticoid systemic therapy within a week prior to entry into the study.\n* Patients receiving other immunotherapy after diagnosis.'}, 'identificationModule': {'nctId': 'NCT03410368', 'briefTitle': 'NK Cell-based Immunotherapy as Maintenance Therapy for Small-Cell Lung Cancer.', 'organization': {'class': 'OTHER', 'fullName': 'The First Hospital of Jilin University'}, 'officialTitle': 'A Randomized, Controlled, Open-label, Single Center, Phase II Study to Evaluate the Efficacy and Safety of NK Cell-based Immunotherapy as Maintenance Therapy for Patients With Small-cell Lung Cancer After First-line Chemotherapy.', 'orgStudyIdInfo': {'id': 'FHJLU-001'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'autologous natural killer cells', 'description': 'Infusion of 1-2×10\\^9 NK cells every 14 days in the absence of progression or unacceptable toxicity until the 6 courses of treatment.', 'interventionNames': ['Biological: NK cells']}, {'type': 'NO_INTERVENTION', 'label': 'routine follow-up', 'description': 'According to present guideline, no special treatment is advised for patients with SCLC after first-line therapy.They will be followed-up regularly.'}], 'interventions': [{'name': 'NK cells', 'type': 'BIOLOGICAL', 'description': 'Autologous peripheral blood mononuclear cells (PBMCs) are collected by apheresis on D0, then induced into NK cells and infused into the patients 14 days later (D14) as the initial transfusion. There are 3 consecutive transfusion days (D14-D16). The second course of PBMCs collection started D14 before infusion. A total of 6 courses will be completed unless progression or unacceptable adverse events.', 'armGroupLabels': ['autologous natural killer cells']}]}, 'contactsLocationsModule': {'locations': [{'zip': '130021', 'city': 'Ch’ang-ch’un', 'state': 'Jilin', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'xuan j li, master', 'role': 'CONTACT', 'email': '1776514587@qq.com', 'phone': '18844194678'}, {'name': 'lei qian, master', 'role': 'CONTACT', 'email': 'qianlei_cool@126.com', 'phone': '15843139762'}], 'facility': 'the First Hospital of Jilin University', 'geoPoint': {'lat': 42.74694, 'lon': 126.24667}}], 'centralContacts': [{'name': 'lei qian, MD', 'role': 'CONTACT', 'email': 'qianlei_cool@126.com', 'phone': '13086891158'}], 'overallOfficials': [{'name': 'jiuwei cui, PhD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'the Cancer Center of First Hospital of Jilin University'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'jiuwei cui', 'class': 'OTHER'}, 'responsibleParty': {'type': 'SPONSOR_INVESTIGATOR', 'investigatorTitle': 'chief', 'investigatorFullName': 'jiuwei cui', 'investigatorAffiliation': 'The First Hospital of Jilin University'}}}}